Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 94.63% is in line with its 5-year average of 98.38%, near the high end of its 5-year range (-38528.57%–100.00%).
0.26% below its 12-month average of 94.88%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 99.42%.
GROSS MARGIN
94.63%
GROSS MARGIN AVG TTM
94.88%
GROSS MARGIN AVG 3Y
99.82%
GROSS MARGIN AVG 5Y
98.38%
GROSS MARGIN AVG 10Y
99.94%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.26%
CURRENT VS 3Y AVG
-5.20%
CURRENT VS 5Y AVG
-3.81%
CURRENT VS 10Y AVG
-5.31%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
37.56%
median of 685 covered companies
CURRENT VS SECTOR MEDIAN
+151.94%
vs the sector median at left
ImmunityBio, Inc.
Market Cap
$10.44B
Gross Margin
94.63%
TTM Avg
94.88%
3Y Avg
99.82%
5Y Avg
98.38%
Market Cap
$10.31B
Gross Margin
68.55%
TTM Avg
63.16%
3Y Avg
66.39%
5Y Avg
68.84%
Market Cap
$10.24B
Gross Margin
66.48%
TTM Avg
69.16%
3Y Avg
69.73%
5Y Avg
70.75%
Market Cap
$10.13B
Gross Margin
14.14%
TTM Avg
15.74%
3Y Avg
16.11%
5Y Avg
16.54%
Market Cap
$10.76B
Gross Margin
90.69%
TTM Avg
90.21%
3Y Avg
89.67%
5Y Avg
89.38%
Market Cap
$10.00B
Gross Margin
13.07%
TTM Avg
12.36%
3Y Avg
12.43%
5Y Avg
12.55%
Market Cap
$9.98B
Gross Margin
51.90%
TTM Avg
52.87%
3Y Avg
53.77%
5Y Avg
54.60%
Market Cap
$10.97B
Gross Margin
63.64%
TTM Avg
63.66%
3Y Avg
64.40%
5Y Avg
64.61%
Market Cap
$11.03B
Gross Margin
75.55%
TTM Avg
78.40%
3Y Avg
77.70%
5Y Avg
76.19%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | $10.44B | 94.63% | 94.88% | 99.82% | 98.38% |
| Globus Medical, Inc. (GMED)vs › | $10.31B | 68.55% | 63.16% | 66.39% | 68.84% |
| Align Technology, Inc. (ALGN)vs › | $10.24B | 66.48% | 69.16% | 69.73% | 70.75% |
| The Ensign Group, Inc. (ENSG)vs › | $10.13B | 14.14% | 15.74% | 16.11% | 16.54% |
| Universal Health Services, Inc. (UHS)vs › | $10.76B | 90.69% | 90.21% | 89.67% | 89.38% |
| Molina Healthcare, Inc. (MOH)vs › | $10.00B | 13.07% | 12.36% | 12.43% | 12.55% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.98B | 51.90% | 52.87% | 53.77% | 54.60% |
| The Cooper Companies, Inc. (COO)vs › | $10.97B | 63.64% | 63.66% | 64.40% | 64.61% |
| BioMarin Pharmaceutical Inc. (BMRN)vs › | $11.03B | 75.55% | 78.40% | 77.70% | 76.19% |
| Krystal Biotech, Inc. (KRYS)vs › | $9.78B | 93.34% | 92.85% | 69.90% | 46.60% |
Gross Margin
94.6%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 99.42% |
| 2026-03-31 | 99.46% |
| 2025-12-31 | 88.91% |
| 2025-09-30 | 87.12% |
| 2025-06-30 | 99.49% |
| 2025-03-31 | 99.65% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | 100.00% |
| 2023-09-30 | 100.00% |
| 2023-06-30 | 100.00% |
| 2023-03-31 | -1643.89% |
| 2022-12-31 | -9321.92% |
| 2022-09-30 | -4963.56% |
| 2022-06-30 | -16845.71% |
| 2022-03-31 | -38528.57% |
| 2021-12-31 | 100.00% |
| 2021-09-30 | 100.00% |
| 2021-06-30 | 100.00% |
| 2021-03-31 | 100.00% |
| 2020-12-31 | -10600.00% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | 100.00% |
| 2019-12-31 | 100.00% |
| 2019-09-30 | 100.00% |
| 2019-06-30 | 100.00% |
| 2019-03-31 | 100.00% |
| 2018-12-31 | 100.00% |
| 2018-09-30 | 100.00% |
| 2018-06-30 | 100.00% |
| 2018-03-31 | 100.00% |
| 2017-12-31 | 100.00% |
| 2017-09-30 | 100.00% |
| 2017-06-30 | 100.00% |
| 2017-03-31 | 100.00% |
| 2016-12-31 | 100.00% |
| 2016-09-30 | 100.00% |
| 2016-06-30 | 100.00% |
| 2016-03-31 | 100.00% |
| 2015-12-31 | 100.00% |
| 2015-09-30 | 100.00% |
| 2015-06-30 | 100.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
